4.5 Article

The transition to Xpert MTB/RIF ultra: diagnostic accuracy for pulmonary tuberculosis in Kampala, Uganda

期刊

BMC INFECTIOUS DISEASES
卷 21, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12879-020-05727-8

关键词

Tuberculosis; Diagnostics; Xpert ultra; Xpert MTB; RIF; Uganda

资金

  1. Bill and Melinda Gates Foundation Trust through Global Good Fund at Intellectual Ventures
  2. Pulmonary Complications of AIDS Research Training (PART) Program (National Institutes of Health-Fogarty International Center) [D43TW009607]
  3. Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12 HD000850]

向作者/读者索取更多资源

In Kampala, Uganda, the evaluation of Ultra cartridge for pulmonary tuberculosis diagnosis among adults showed a sensitivity of 90.5% and specificity of 98.1%, with no significant differences compared to Xpert. Considering trace results as positive increased case detection without significant loss of specificity.
BackgroundThe World Health Organization (WHO) has endorsed the next-generation Xpert MTB/RIF Ultra (Ultra) cartridge, and Uganda is currently transitioning from the older generation Xpert MTB/RIF (Xpert) cartridge to Ultra as the initial diagnostic test for pulmonary tuberculosis (TB). We assessed the diagnostic accuracy of Ultra for pulmonary TB among adults in Kampala, Uganda.MethodsWe sampled adults referred for Xpert testing at two hospitals and a health center over a 12-month period. We enrolled adults with positive Xpert and a random 1:1 sample with negative Xpert results. Expectorated sputum was collected for Ultra, and for solid and liquid culture testing for Xpert-negative patients. We measured sensitivity and specificity of Ultra overall and by HIV status, prior history of TB, and hospitalization, in reference to Xpert and culture results. We also assessed how classification of results in the new trace category affects Ultra accuracy.ResultsAmong 698 participants included, 211 (30%) were HIV-positive and 336 (48%) had TB. The sensitivity of Ultra was 90.5% (95% CI 86.8-93.4) and specificity was 98.1% (95% CI 96.1-99.2). There were no significant differences in sensitivity and specificity by HIV status, prior history of TB or hospitalization. Xpert and Ultra results were concordant in 670 (96%) participants, with Ultra having a small reduction in specificity (difference 1.9, 95% CI 0.2 to 3.6, p=0.01). When trace results were considered positive for all patients, sensitivity increased by 2.1% (95% CI 0.3 to 3.9, p=0.01) without a significant reduction in specificity (-0.8, 95% CI -0.3 to 2.0, p=0.08).ConclusionsAfter 1 year of implementation, Ultra had similar performance to Xpert. Considering trace results to be positive in all patients increased case detection without significant loss of specificity. Longitudinal studies are needed to compare the benefit of greater diagnoses to the cost of overtreatment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据